InStride Health is a technology company.
InStride Health has raised $61.0M across 3 funding rounds.
InStride Health has raised $61.0M in total across 3 funding rounds.
InStride Health has raised $61.0M in total across 3 funding rounds.
InStride Health's investors include Bain Capital Ventures, General Catalyst, Lerer Hippeau, Sarah Smith Fund, Y Combinator, .406 Ventures, BlueCross BlueShield Venture Partners, Flare Capital Partners, Forgepoint Capital, Founders Co-op, Obvious Ventures, Cathay Health.
# InStride Health: A Healthcare Company, Not a Technology Company
InStride Health is primarily a healthcare provider, not a technology company. While it leverages technology as an enabler, its core business is delivering specialty mental health treatment for anxiety and OCD in children, adolescents, and young adults[1][2].
InStride Health is an insurance-backed mental health provider that delivers evidence-based anxiety and OCD treatment through a virtual, technology-enhanced outpatient care model[2]. The company serves pediatric and young adult patients (ages 7-22) who struggle with moderate to severe anxiety and OCD, along with their families[6].
The company's core offering is a multidisciplinary care team approach that pairs each patient with a psychiatrist, therapist, and exposure coach who provide individual therapy, group therapy, medication management, and real-world coaching[3]. Rather than building software products, InStride has built a scalable clinical delivery model that emphasizes "the human touch" while using technology to improve access and affordability[2].
InStride Health was co-founded by Drs. Mona Potter and Kathryn Boger, both Harvard-trained clinicians who previously worked together for over a decade at a leading freestanding psychiatric hospital[1]. The two clinicians co-developed the McLean Anxiety Mastery Program (MAMP) at McLean Hospital, a nationally recognized program for treating children and adolescents with moderate to severe anxiety and OCD[2].
Recognizing the growing pediatric mental health crisis and the gap in accessible specialty care, Potter and Boger founded InStride to make their proven clinical model scalable and accessible through an insurance-backed approach[1]. The company's care model is grounded in the clinical outcomes and hands-on experience from MAMP[2].
InStride operates within the pediatric mental health crisis, where demand for specialty anxiety and OCD treatment far exceeds available capacity[1][2]. The company addresses a critical gap: while corporate America spends billions on mental health initiatives, access to evidence-based specialty care for young people remains limited and fragmented.
The company's expansion strategy reflects broader healthcare trends toward virtual care delivery and insurance-based models that improve access without sacrificing clinical quality. By operating in 12 states and accepting insurance, InStride is positioned to scale specialty mental health care beyond traditional hospital-based settings[3].
InStride Health is executing a clinical scaling strategy rather than a technology scaling strategy. Recent leadership additions—including a new Senior Vice President of Payor Growth & Strategy—signal the company's focus on expanding insurance partnerships and geographic reach[3]. With 321 employees and operations across 12 states, the company is positioned to grow its care delivery footprint while maintaining clinical excellence.
The company's future hinges on its ability to demonstrate measurable clinical outcomes and insurance reimbursement sustainability, not on building proprietary technology platforms. Success will be measured by treatment efficacy, patient outcomes, and the ability to scale evidence-based care to more families—a healthcare challenge, not a technology one.
InStride Health has raised $61.0M across 3 funding rounds. Most recently, it raised $30.0M Series B in March 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2024 | $30.0M Series B | Bain Capital Ventures, General Catalyst, Lerer Hippeau, Sarah Smith Fund, Y Combinator | |
| Oct 1, 2022 | $26.0M Series A | .406 Ventures, BlueCross BlueShield Venture Partners, Flare Capital Partners, Forgepoint Capital, Founders Co-op, Obvious Ventures | |
| Sep 1, 2022 | $5.0M Series A | Cathay Health, Endeavor Venture Funds, New Enterprise Associates (NEA), Soffinova Partners, Sonder Capital |